Horizon Pharma plc s chart and data analysis indicates that the stock price has dropped -12.31% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 1.1% . Looking at the past 52 week period, the stock price is down -11.82% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Horizon Pharma plc has a negative value of -2.35 compared to overall market performance.
Horizon Pharma plc stock has recorded a 20-day Moving Average of 4.85% and the 50-Day Moving Average is 5.28%.The 200 Day SMA reached 3.26%Horizon Pharma plc is having a Relative Strength Index of 59.37 which indicates the stock is not yet over sold or over bought based on the technical indicators. Horizon Pharma plc (NASDAQ:HZNP) has climbed 2.86% in the past week and advanced 9.34% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 2.16% and the outperformance has advanced to 5.98% for the last 4 weeks period.
Horizon Pharma plc (NASDAQ:HZNP) : On Friday heightened volatility was witnessed in Horizon Pharma plc (NASDAQ:HZNP) which led to swings in the share price. The stock opened for trading at $16.98 and hit $17.69 on the upside , eventually ending the session at $17.45, with a gain of 1.75% or 0.3 points. The heightened volatility saw the trading volume jump to 3,923,580 shares. The 52-week high of the share price is $23.444 and the company has a market cap of $2,814 million. The 52-week low of the share price is at $13.0501 .
Currently the company Insiders own 2.1% of Horizon Pharma plc shares according to the proxy statements. Institutional Investors own 86.67% of Horizon Pharma plc shares. Company has reported several Insider transactions to the SEC, on Aug 2, 2016, Jeffrey W Sherman (EVP and Chief Medical Officer) sold 2,900 shares at 20.00 per share price.On Jun 15, 2016, Virinder Nohria (director) sold 25,000 shares at 17.69 per share price.On Aug 21, 2015, Thomas Watkins (director) purchased 10,000 shares at 31.32 per share price.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Company shares were Upgraded by Mizuho on Dec 16, 2016 to Buy, Raises Price Target to $ 25 from a previous price target of $14 .Horizon Pharma PLC was Downgraded by Mizuho on Dec 9, 2016 to Neutral, Lowers Price Target to $ 14 from a previous price target of $30 .Horizon Pharma PLC was Upgraded by Citigroup to Buy on Nov 28, 2016.
Horizon Pharma PLC Last issued its quarterly earnings results on Nov 7, 2016. The company reported $0.70 EPS for the quarter, beating the analyst consensus estimate by $ 0.08. Analyst had a consensus of $0.62. The company had revenue of $273.70 million for the quarter, compared to analysts expectations of $272.03 million. The companys revenue was up 20.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.70 EPS.
Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases. The companys U.S. marketed products are ACTIMMUNE? (interferon gamma-1b), DUEXIS? (ibuprofen/famotidine), PENNSAID? (diclofenac sodium topical solution) 2% w/w, RAYOS? (prednisone) delayed-release tablets and VIMOVO? (naproxen/esomeprazole magnesium). Horizons global headquarters are in Dublin, Ireland.